Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods We …

Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process, …

Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–…

Objective To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid
arthritis (JRA). Methods This was an international, multicenter, randomized, placebo‐…

Objective To describe the clinical, laboratory, and histopathologic features, current treatment,
and outcome of patients with macrophage activation syndrome (MAS) complicating …

Objective Juvenile localized scleroderma is usually considered a disease that is confined to
the skin and subcutaneous tissue. We studied the prevalence and clinical features of …

Macrophage activation syndrome (MAS) is a rare and potentially fatal disorder, thought to
result from uncontrolled activation and proliferation of T cells and excessive activation of …

Epidemiological and clinical reports indicate that SARS-CoV-2 virulence hinges upon the
triggering of an aberrant host immune response, more so than on direct virus-induced cellular …

Objective. To study the long‐term effects of supplementation with omega‐3 fatty acids (ω3)
in patients with active rheumatoid arthritis. Methods. Ninety patients were enrolled in a 12‐…

Objective To describe the clinical and laboratory features of macrophage activation syndrome
as a complication of juvenile systemic lupus erythematosus (SLE). Methods Cases of …